Correlation Engine 2.0
Clear Search sequence regions


  • brain (6)
  • diagnosis (1)
  • gnrh receptor (3)
  • gnrh receptor (2)
  • humans (1)
  • ligand (4)
  • liver (2)
  • photon (4)
  • radiopharmaceuticals (1)
  • rats (1)
  • receptor (1)
  • serum (3)
  • Sizes of these terms reflect their relevance to your search.

    The increased expression of gonadotropin releasing hormone receptor (GnRH-R) in brain has been strongly linked to Alzheimer disease. Therefore, the development of radiolabeled imaging agents for GnRH-R is relevant for early diagnosis of Alzheimer disease. We have recently disclosed the discovery of two promising compounds displaying nanomolar-range affinity for the GnRH-R. In the present study, a preclinical evaluation of the compound properties was performed to evaluate their potential as single photon emission computed tomography (SPECT) radiotracers for imaging the GnRH-receptor. The compounds were assessed in vitro by performing serum stability analysis by human and rat serum, metabolic profiling by human liver microsomes, and exploratory rat brain autoradiography. The investigated compounds displayed satisfactory stability against human, rat serum, and liver microsomal metabolism, which favors their potential as SPECT-imaging agents. Additionally, we identified and quantified the formation rate of the metabolites by fragmentation of up to five mass spectrometric stages. The GnRH-R rat brain specificity of these compounds was tested in competition with a known ligand for the receptor and the in vitro autoradiography confirmed that compounds 3 and 4 binds to rat GnRH-R in different rat brain regions. © 2019 The Authors. Journal of Labelled Compounds and Radiopharmaceuticals published by John Wiley & Sons Ltd.

    Citation

    Richard Fjellaksel, Angel Moldes-Anaya, Terje Vasskog, Ana Oteiza, Montserrat Martin-Armas, Ole Kristian Hjelstuen, Jørn H Hansen, Patrick J Riss, Rune Sundset. Evaluation by metabolic profiling and in vitro autoradiography of two promising GnRH-receptor ligands for brain SPECT imaging. Journal of labelled compounds & radiopharmaceuticals. 2020 Feb;63(2):72-84

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 31813158

    View Full Text